Slide 1: Investor Presentation Q2FY24
Investor Presentation Q2FY24 27-10-2023 1
Slide 2: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Q2FY24: Revenue up YoY by 15%; Margin expansion YoY by 350+ bps
Q2FY24 : Revenue up YoY by 15%; Margin expansion YoY by 350+ bps Strong performance delivered across key markets; robust operating profitability sustained KEY HIGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 INR 6,678 Cr 15% INR 1,734 Cr 33% YoY (YoY) 26.0% of revenue 5.7% 13% 33% of reported
Slide 4: Financial Performance – Q2FY24
Financial Performance – Q2FY24 Revenues INR 6,678 Cr EBITDA INR 1,734 Cr Revenue1 Break-up Q2FY24 (Consolidated) Actuals International API, 2% Others, 2% vs Q2 FY23 (INR Cr) Markets, 11% Total Revenue from 6,678 14.6% Operations QCIL, 3% EBITDA 1,734 33.1% India, 42% EBITDA % 26.0% 362 bps SAGA Excl
Slide 5: Healthy Cash position – Continued focus on building balance sheet strength
Healthy Cash position – Continued focus on building balance sheet strength INR Cr Total Debt1 Cash Balance2 Net Cash3 Post dividend payment of INR 686Cr 6,138 6,941 6,811 5,850 5,469 6,273 803 961 803 Mar'23 Jun'23 Sep'23 Mar'23 Jun'23 Sep'23 Mar'23 Jun'23 Sep'23 1. Total debt includes lease liabili
Slide 6: Efficient Capital Allocation – Investments & Divestment decisions
Efficient Capital Allocation – Investments & Divestment decisions Investment Divestment Divestment • Strategic Investment in Actor • Strategic divestment in Cipla Pharma, South Africa to Quality Chemical Industries Ltd to • Strategic divestment in Saba focus on capital allocation on Investment Ltd (
Slide 7: One India: Robust portfolio traction across therapies and business segments
One India1 : Robust portfolio traction across therapies and business segments INR Cr One India business TTM revenue trend One India business Q2 YoY revenue trend Ex-covid Ex-covid CAGR CAGR 13% 16% 2,817 10,407 2,572 9,303 2,234 8,166 1,794 Q2 F Y21 Q2 F Y22 Q2 F Y23 Q2 F Y24 TTM Sep-21 TTM Sep-22 T
Slide 8: India Respiratory leadership: Creating awareness for patients 'Beyond the Pill'
India Respiratory leadership : Creating awareness for patients ‘Beyond the Pill’ Berok Zindagi 6.0 Tuffies Spirofy Synchrobreathe Asthma awareness Pediatric Asthma Device and Diagnostics Device and Diagnostics awareness ❑ New ‘Inhalers Hain Sahi ❑ India’s first pneumotach ❑ Successfully launched ❑ S
Slide 9: H1 FY2024 Global Consumer Wellness Franchise
H1 FY2024 Global Consumer Wellness Franchise : Holistic wellness solutions and improving health outcomes One India Consumer brands in India Pain relief Nicotine Replacement Hydration Skin infection Cold & cough ~8% INR 699 Cr INR 130+ Cr INR ~90 Cr INR 141C`r INR 85+ Cr INR 65+ Cr INR 45+ Cr Contrib
Slide 10: North America: Consistent expansion in business trajectory
North America: Consistent expansion in business trajectory backed by growth in base business and key assets 14th consecutive quarter of growth in revenue over previous year $ Mn 28% 26% 229 222 204 195 179 160 155 150 141 142 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 10
Slide 11: North America: Robust momentum in differentiated portfolio
North America: Robust momentum in differentiated portfolio Key Business Highlights North America • Highest ever quarterly revenue at $229 Mn with a strong $ Mn Q2 FY24 YoY double-digit quarterly growth of 28% YoY for Q2 FY24 229 • Continuous efforts on expanding Lanreotide’s market share : improved
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th Sep 2023)
ANDA & NDA Portfolio & Pipeline (As on 30th Sep 2023) 14 59 9 4 20 8 79 2 1 48 20 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 161 1 31 80 272 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDA
Slide 13: SAGA: Steady growth in Private Market, Highest-ever quarterly revenue
SAGA1: Steady growth in Private Market, Highest-ever quarterly revenue ZAR Mn South Africa Q2 YoY comparison 202 ❖ Private market recorded highest ever quarterly primary revenue 6 216 of ~ZAR 1200Mn, delivered 12% YoY growth in ZAR terms 1,197 ❖ In secondary terms, strong demand continues with overa
Slide 14: Actor Pharma acquisition: Strengthening SA OTC
Actor Pharma acquisition : Strengthening SA OTC Key positives FY 2023 Sales : ZAR 233.6 Mn Expand Cipla’s reach to enhanced range of therapies and wider basket of product portfolio (2 years CAGR : 23%) Baby and Robust cash generating business with net cash position Child, 12% Generics, 23% Growing f
Slide 15: International Markets & API
International Markets & API International Markets API Q2 FY24 Revenue $ Mn Q2 FY24 Revenue $ Mn 96 19 18 89 Q2FY23 Q2FY24 Q2FY23 Q2FY24 15
Slide 16: ESG Update
ESG Update Progress on ESG : YTD Aug’2023 Goa sites certified for Zero Waste to Landfill 31.6% Renewable Energy in the energy mix vs 26.2% in YTD Aug-22 6.9% YoY reduction in absolute GHG emission for scope 1 (fuel based) and scope 2 3.4 % reduction in freshwater withdrawal 43.7% of water recycled a
Slide 17: Profit and Loss statement summary
Profit and Loss statement summary Q2 FY24 Q2 FY23 Particulars (INR Cr) (INR Cr) Revenue from sale of products 6,589 5,759 Other operating income 89 69 Income from operations 6,678 5,829 Material cost 2,313 2,160 Employee benefits expense 1,091 961 Other expenses 1,540 1,405 Total expenses 4,944 4,52
Slide 18: Balance sheet as on 30th September 2023
Balance sheet as on 30th September 2023 INR Cr Particulars Sep-23 Jun-23 Mar-23 Net tangible assets 5,725 5,750 5,740 Goodwill and other intangibles 4,464 4,426 4,514 Investments 561 571 573 Other non-current assets 364 317 352 Income tax assets (net) 346 333 531 Deferred tax assets (net) 346 307 29
Slide 19: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.ci